Rico H, Hernandez E R, Revilla M, Gómez-Castresana F
Department of Medicine, Alcalá de Henares University, Madrid, Spain.
Bone Miner. 1992 Feb;16(2):131-8. doi: 10.1016/0169-6009(92)90883-f.
The effectiveness of calcitonin on the vertebral fracture rate in postmenopausal osteoporosis was assessed through the skeletal deformity index (SDI) and the new vertebral fracture rate per 100 patient-years in a group of 32 women with postmenopausal osteoporosis treated by us with 100 IU of salmon calcitonin and 500 mg of elemental calcium for 10 consecutive days each month, and in another group of 28 women with postmenopausal osteoporosis treated with 500 mg of elemental calcium only for 10 consecutive days each month. Both groups were age-matched. The follow-up was a retrospective randomized study over 24 months. Thirty of the 32 women of the calcitonin group and 27 of 28 women of the calcium group finished treatment. The SDI was stabilized after six months in the calcitonin group (0.57 +/- 0.13, 0.62 +/- 0.18, 0.63 +/- 0.16 and 0.64 +/- 0.17, at base line, 6, 12 and 24 months respectively). The calcium group showed a significant increase only at 12 months (P less than 0.01) and 24 months (P less than 0.05) (0.61 +/- 0.16, 0.63 +/- 0.16, 0.69 +/- 0.16, and 0.73 +/- 0.15, at base line, 6, 12 and 24 months respectively). At 24 months, the new vertebral fracture rate decreased by 60% (20%, 14% and 8% at 6, 12 and 24 months respectively) in the calcitonin group and increased by 35% (31%, 33% and 42%, at 6, 12 and 24 months respectively) in the calcium group (P less than 0.025). These results show that calcitonin induced a significant reduction in postmenopausal osteoporotic vertebral fractures.
通过骨骼畸形指数（SDI）和每100患者年的新椎体骨折率，对降钙素在绝经后骨质疏松症患者椎体骨折率方面的有效性进行了评估。我们将一组32名绝经后骨质疏松症女性患者，每月连续10天给予100 IU鲑鱼降钙素和500 mg元素钙进行治疗；另一组28名绝经后骨质疏松症女性患者，每月仅连续10天给予500 mg元素钙进行治疗。两组年龄匹配。随访为一项为期24个月的回顾性随机研究。降钙素组的32名女性中有30名、钙组的28名女性中有27名完成了治疗。降钙素组在6个月后SDI趋于稳定（基线时为0.57±0.13，6个月时为0.62±0.18，12个月时为0.63±0.16，24个月时为0.64±0.17）。钙组仅在12个月（P<0.01）和24个月（P<0.05）时出现显著增加（基线时为0.61±0.16，6个月时为0.63±0.16，12个月时为0.69±0.16，24个月时为0.73±0.15）。在24个月时，降钙素组的新椎体骨折率下降了60%（6个月、12个月和24个月时分别为20%、14%和8%），而钙组则增加了35%（6个月、12个月和24个月时分别为31%、33%和42%）（P<0.025）。这些结果表明，降钙素可显著降低绝经后骨质疏松性椎体骨折的发生率。
